Stem definition | Drug id | CAS RN |
---|---|---|
HIV protease inhibitors | 1601 | 192725-17-0 |
Dose | Unit | Route |
---|---|---|
0.80 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2.20 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 24.22 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 15, 2000 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 1210.98 | 23.46 | 605 | 13223 | 124255 | 53210983 |
Abortion spontaneous | 720.90 | 23.46 | 313 | 13515 | 46322 | 53288916 |
Off label use | 581.72 | 23.46 | 658 | 13170 | 471554 | 52863684 |
Foetal exposure during pregnancy | 522.97 | 23.46 | 229 | 13599 | 34486 | 53300752 |
Stillbirth | 479.39 | 23.46 | 141 | 13687 | 6656 | 53328582 |
Abortion induced | 414.79 | 23.46 | 141 | 13687 | 10685 | 53324553 |
Virologic failure | 338.78 | 23.46 | 85 | 13743 | 2179 | 53333059 |
Viral mutation identified | 331.03 | 23.46 | 82 | 13746 | 1992 | 53333246 |
Drug interaction | 264.77 | 23.46 | 304 | 13524 | 219025 | 53116213 |
Foetal death | 263.66 | 23.46 | 97 | 13731 | 9250 | 53325988 |
Maternal exposure during pregnancy | 259.07 | 23.46 | 256 | 13572 | 155383 | 53179855 |
Premature baby | 248.15 | 23.46 | 115 | 13713 | 19686 | 53315552 |
Immune reconstitution inflammatory syndrome | 224.86 | 23.46 | 78 | 13750 | 6268 | 53328970 |
Drug resistance | 219.64 | 23.46 | 106 | 13722 | 19856 | 53315382 |
Hypomania | 200.37 | 23.46 | 67 | 13761 | 4815 | 53330423 |
Jaundice cholestatic | 199.86 | 23.46 | 69 | 13759 | 5465 | 53329773 |
Live birth | 193.45 | 23.46 | 89 | 13739 | 14970 | 53320268 |
Hepatotoxicity | 162.42 | 23.46 | 97 | 13731 | 27783 | 53307455 |
Premature rupture of membranes | 160.76 | 23.46 | 57 | 13771 | 4883 | 53330355 |
Pregnancy | 159.18 | 23.46 | 100 | 13728 | 31341 | 53303897 |
Schizophrenia | 155.11 | 23.46 | 68 | 13760 | 10211 | 53325027 |
Premature labour | 152.34 | 23.46 | 71 | 13757 | 12291 | 53322947 |
Caesarean section | 138.04 | 23.46 | 74 | 13754 | 17246 | 53317992 |
Blood HIV RNA increased | 134.35 | 23.46 | 33 | 13795 | 772 | 53334466 |
Pathogen resistance | 127.65 | 23.46 | 52 | 13776 | 6508 | 53328730 |
Fanconi syndrome acquired | 119.93 | 23.46 | 32 | 13796 | 1049 | 53334189 |
Blood bilirubin increased | 119.62 | 23.46 | 88 | 13740 | 35642 | 53299596 |
Viral load increased | 114.54 | 23.46 | 33 | 13795 | 1442 | 53333796 |
HIV infection | 112.78 | 23.46 | 27 | 13801 | 565 | 53334673 |
Premature delivery | 112.35 | 23.46 | 75 | 13753 | 26029 | 53309209 |
Psychotic disorder | 109.64 | 23.46 | 72 | 13756 | 24313 | 53310925 |
Ergot poisoning | 107.93 | 23.46 | 22 | 13806 | 210 | 53335028 |
Treatment noncompliance | 107.52 | 23.46 | 80 | 13748 | 32955 | 53302283 |
Lipodystrophy acquired | 102.25 | 23.46 | 31 | 13797 | 1619 | 53333619 |
CD4 lymphocytes decreased | 97.08 | 23.46 | 30 | 13798 | 1671 | 53333567 |
Skull malformation | 87.63 | 23.46 | 20 | 13808 | 337 | 53334901 |
COVID-19 pneumonia | 87.58 | 23.46 | 41 | 13787 | 7162 | 53328076 |
Spina bifida | 81.39 | 23.46 | 22 | 13806 | 758 | 53334480 |
Long QT syndrome | 77.65 | 23.46 | 30 | 13798 | 3266 | 53331972 |
Pain | 77.62 | 23.46 | 28 | 13800 | 588370 | 52746868 |
Cholelithiasis | 74.66 | 23.46 | 71 | 13757 | 40893 | 53294345 |
Human immunodeficiency virus transmission | 68.80 | 23.46 | 13 | 13815 | 80 | 53335158 |
Fatigue | 68.27 | 23.46 | 54 | 13774 | 730452 | 52604786 |
Genotype drug resistance test positive | 68.17 | 23.46 | 18 | 13810 | 566 | 53334672 |
Electrocardiogram QT prolonged | 67.36 | 23.46 | 78 | 13750 | 56325 | 53278913 |
COVID-19 | 67.34 | 23.46 | 64 | 13764 | 36824 | 53298414 |
Foetal growth restriction | 66.70 | 23.46 | 34 | 13794 | 7140 | 53328098 |
Immunosuppressant drug level increased | 65.89 | 23.46 | 27 | 13801 | 3428 | 53331810 |
Trisomy 21 | 64.50 | 23.46 | 16 | 13812 | 390 | 53334848 |
Normal newborn | 60.93 | 23.46 | 32 | 13796 | 7147 | 53328091 |
Cushing's syndrome | 59.06 | 23.46 | 17 | 13811 | 740 | 53334498 |
Cerebral ventricle dilatation | 57.96 | 23.46 | 18 | 13810 | 1019 | 53334219 |
Portal hypertension | 57.32 | 23.46 | 25 | 13803 | 3703 | 53331535 |
Hyperbilirubinaemia | 55.45 | 23.46 | 35 | 13793 | 11034 | 53324204 |
Eosinophilia | 54.93 | 23.46 | 45 | 13783 | 21290 | 53313948 |
Fall | 54.57 | 23.46 | 13 | 13815 | 358427 | 52976811 |
Pre-eclampsia | 52.71 | 23.46 | 31 | 13797 | 8616 | 53326622 |
Dyspnoea | 49.03 | 23.46 | 48 | 13780 | 586184 | 52749054 |
Drug ineffective | 46.21 | 23.46 | 89 | 13739 | 817156 | 52518082 |
Hepatocellular injury | 45.41 | 23.46 | 47 | 13781 | 29939 | 53305299 |
Placental disorder | 43.56 | 23.46 | 16 | 13812 | 1515 | 53333723 |
Patent ductus arteriosus | 42.65 | 23.46 | 21 | 13807 | 4097 | 53331141 |
Hepatic cytolysis | 42.19 | 23.46 | 26 | 13802 | 7859 | 53327379 |
Rash maculo-papular | 42.14 | 23.46 | 45 | 13783 | 29704 | 53305534 |
Arnold-Chiari malformation | 41.87 | 23.46 | 12 | 13816 | 514 | 53334724 |
Rickets | 41.45 | 23.46 | 8 | 13820 | 56 | 53335182 |
Alopecia | 41.02 | 23.46 | 6 | 13822 | 234577 | 53100661 |
Renal tubular dysfunction | 40.47 | 23.46 | 11 | 13817 | 387 | 53334851 |
Renal tubular disorder | 40.15 | 23.46 | 18 | 13810 | 2845 | 53332393 |
Vomiting | 39.84 | 23.46 | 242 | 13586 | 496897 | 52838341 |
Hepatic enzyme increased | 38.08 | 23.46 | 94 | 13734 | 126101 | 53209137 |
Placenta praevia | 37.98 | 23.46 | 13 | 13815 | 1001 | 53334237 |
Arthralgia | 37.89 | 23.46 | 35 | 13793 | 439748 | 52895490 |
Acquired immunodeficiency syndrome | 37.27 | 23.46 | 8 | 13820 | 100 | 53335138 |
Peripheral swelling | 36.66 | 23.46 | 5 | 13823 | 206103 | 53129135 |
Coarctation of the aorta | 36.23 | 23.46 | 11 | 13817 | 577 | 53334661 |
Neural tube defect | 36.22 | 23.46 | 9 | 13819 | 221 | 53335017 |
Anticoagulation drug level increased | 36.10 | 23.46 | 9 | 13819 | 224 | 53335014 |
Urinary tract infection | 35.89 | 23.46 | 9 | 13819 | 239894 | 53095344 |
Polydactyly | 35.65 | 23.46 | 10 | 13818 | 396 | 53334842 |
Swelling | 35.54 | 23.46 | 4 | 13824 | 191101 | 53144137 |
Gene mutation | 35.00 | 23.46 | 13 | 13815 | 1270 | 53333968 |
Placental insufficiency | 34.11 | 23.46 | 13 | 13815 | 1363 | 53333875 |
Pulmonary tuberculosis | 33.75 | 23.46 | 19 | 13809 | 4862 | 53330376 |
Product dose omission issue | 33.26 | 23.46 | 5 | 13823 | 191615 | 53143623 |
Ventricular septal defect | 33.00 | 23.46 | 18 | 13810 | 4332 | 53330906 |
Mitochondrial cytopathy | 32.70 | 23.46 | 9 | 13819 | 332 | 53334906 |
Atrial septal defect | 32.49 | 23.46 | 21 | 13807 | 6893 | 53328345 |
Congenital anomaly | 32.07 | 23.46 | 13 | 13815 | 1604 | 53333634 |
Gestational diabetes | 31.95 | 23.46 | 22 | 13806 | 8017 | 53327221 |
Brachydactyly | 31.62 | 23.46 | 7 | 13821 | 102 | 53335136 |
Anaemia | 31.14 | 23.46 | 148 | 13680 | 276570 | 53058668 |
Dysmorphism | 31.09 | 23.46 | 14 | 13814 | 2236 | 53333002 |
Renal tubular acidosis | 31.07 | 23.46 | 13 | 13815 | 1738 | 53333500 |
Nephropathy toxic | 30.68 | 23.46 | 22 | 13806 | 8550 | 53326688 |
Drug reaction with eosinophilia and systemic symptoms | 30.48 | 23.46 | 40 | 13788 | 32760 | 53302478 |
Oligohydramnios | 29.90 | 23.46 | 19 | 13809 | 6057 | 53329181 |
Cardiac malposition | 29.55 | 23.46 | 6 | 13822 | 56 | 53335182 |
Hypertriglyceridaemia | 29.26 | 23.46 | 19 | 13809 | 6285 | 53328953 |
Maternal drugs affecting foetus | 28.94 | 23.46 | 18 | 13810 | 5528 | 53329710 |
Cerebral toxoplasmosis | 28.79 | 23.46 | 10 | 13818 | 805 | 53334433 |
Constipation | 28.61 | 23.46 | 8 | 13820 | 198404 | 53136834 |
Cholestasis of pregnancy | 28.46 | 23.46 | 11 | 13817 | 1198 | 53334040 |
Transaminases increased | 28.39 | 23.46 | 37 | 13791 | 30095 | 53305143 |
Pregnancy on contraceptive | 28.11 | 23.46 | 11 | 13817 | 1238 | 53334000 |
Foetal malformation | 28.09 | 23.46 | 7 | 13821 | 174 | 53335064 |
Hypophosphataemia | 27.90 | 23.46 | 21 | 13807 | 8784 | 53326454 |
Pain in extremity | 27.86 | 23.46 | 20 | 13808 | 285030 | 53050208 |
Hepatic displacement | 26.86 | 23.46 | 5 | 13823 | 28 | 53335210 |
Congenital eye disorder | 26.29 | 23.46 | 5 | 13823 | 32 | 53335206 |
Spinocerebellar disorder | 25.90 | 23.46 | 5 | 13823 | 35 | 53335203 |
Hyperlactacidaemia | 25.58 | 23.46 | 13 | 13815 | 2712 | 53332526 |
Mental disability | 25.51 | 23.46 | 6 | 13822 | 116 | 53335122 |
Drug hypersensitivity | 25.41 | 23.46 | 19 | 13809 | 265223 | 53070015 |
Benign hydatidiform mole | 24.77 | 23.46 | 6 | 13822 | 132 | 53335106 |
Twin pregnancy | 24.63 | 23.46 | 10 | 13818 | 1239 | 53333999 |
Threatened labour | 24.28 | 23.46 | 9 | 13819 | 874 | 53334364 |
Therapeutic response unexpected | 24.24 | 23.46 | 26 | 13802 | 17244 | 53317994 |
Meningitis cryptococcal | 24.16 | 23.46 | 10 | 13818 | 1301 | 53333937 |
Dizziness | 24.15 | 23.46 | 37 | 13791 | 372222 | 52963016 |
COVID-19 treatment | 24.12 | 23.46 | 6 | 13822 | 148 | 53335090 |
Acute respiratory distress syndrome | 24.11 | 23.46 | 30 | 13798 | 23302 | 53311936 |
Meningomyelocele | 24.03 | 23.46 | 8 | 13820 | 566 | 53334672 |
Coronavirus infection | 23.84 | 23.46 | 13 | 13815 | 3127 | 53332111 |
Abdominal discomfort | 23.64 | 23.46 | 14 | 13814 | 221048 | 53114190 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Off label use | 1311.47 | 15.01 | 1392 | 24301 | 304928 | 32182905 |
Drug interaction | 1192.77 | 15.01 | 1134 | 24559 | 217051 | 32270782 |
Depression | 693.55 | 15.01 | 589 | 25104 | 96471 | 32391362 |
Lipodystrophy acquired | 595.07 | 15.01 | 187 | 25506 | 3495 | 32484338 |
Mitochondrial toxicity | 443.45 | 15.01 | 138 | 25555 | 2492 | 32485341 |
Foetal exposure during pregnancy | 366.49 | 15.01 | 285 | 25408 | 41016 | 32446817 |
Eyelid ptosis | 332.54 | 15.01 | 135 | 25558 | 5407 | 32482426 |
Immune reconstitution inflammatory syndrome | 253.48 | 15.01 | 132 | 25561 | 9427 | 32478406 |
Long QT syndrome | 228.92 | 15.01 | 84 | 25609 | 2547 | 32485286 |
Progressive external ophthalmoplegia | 225.68 | 15.01 | 70 | 25623 | 1248 | 32486585 |
Hypertransaminasaemia | 221.00 | 15.01 | 93 | 25600 | 4081 | 32483752 |
Virologic failure | 209.30 | 15.01 | 87 | 25606 | 3700 | 32484133 |
Diplopia | 199.82 | 15.01 | 131 | 25562 | 14381 | 32473452 |
Hypertriglyceridaemia | 190.82 | 15.01 | 106 | 25587 | 8613 | 32479220 |
Exposure during pregnancy | 187.88 | 15.01 | 107 | 25586 | 9122 | 32478711 |
Fanconi syndrome acquired | 178.60 | 15.01 | 67 | 25626 | 2163 | 32485670 |
Premature baby | 158.00 | 15.01 | 125 | 25568 | 18393 | 32469440 |
Drug-induced liver injury | 150.85 | 15.01 | 136 | 25557 | 23927 | 32463906 |
Hepatic fibrosis | 144.12 | 15.01 | 66 | 25627 | 3552 | 32484281 |
Viral mutation identified | 142.43 | 15.01 | 62 | 25631 | 2957 | 32484876 |
Electrocardiogram QT prolonged | 140.83 | 15.01 | 165 | 25528 | 39476 | 32448357 |
Loss of personal independence in daily activities | 138.21 | 15.01 | 136 | 25557 | 26697 | 32461136 |
COVID-19 | 118.28 | 15.01 | 136 | 25557 | 31879 | 32455954 |
Drug effective for unapproved indication | 107.16 | 15.01 | 41 | 25652 | 1398 | 32486435 |
Fanconi syndrome | 97.83 | 15.01 | 41 | 25652 | 1779 | 32486054 |
Hyperbilirubinaemia | 97.16 | 15.01 | 93 | 25600 | 17637 | 32470196 |
Renal tubular disorder | 97.04 | 15.01 | 57 | 25636 | 5145 | 32482688 |
Pathogen resistance | 96.04 | 15.01 | 71 | 25622 | 9439 | 32478394 |
HIV infection | 95.59 | 15.01 | 41 | 25652 | 1885 | 32485948 |
Kaposi's sarcoma | 93.99 | 15.01 | 34 | 25659 | 988 | 32486845 |
Viral load increased | 93.62 | 15.01 | 47 | 25646 | 3103 | 32484730 |
Death | 92.46 | 15.01 | 100 | 25593 | 382417 | 32105416 |
Trisomy 21 | 89.69 | 15.01 | 28 | 25665 | 510 | 32487323 |
Osteoporosis | 84.60 | 15.01 | 73 | 25620 | 12109 | 32475724 |
Nephropathy toxic | 83.80 | 15.01 | 72 | 25621 | 11874 | 32475959 |
Drug ineffective | 76.33 | 15.01 | 116 | 25577 | 383361 | 32104472 |
COVID-19 pneumonia | 72.50 | 15.01 | 58 | 25635 | 8662 | 32479171 |
Ophthalmoplegia | 69.09 | 15.01 | 30 | 25663 | 1421 | 32486412 |
Volvulus | 67.86 | 15.01 | 29 | 25664 | 1321 | 32486512 |
Drug resistance | 64.49 | 15.01 | 85 | 25608 | 22880 | 32464953 |
Drug level increased | 63.75 | 15.01 | 79 | 25614 | 20001 | 32467832 |
Extraocular muscle paresis | 61.18 | 15.01 | 21 | 25672 | 521 | 32487312 |
Hyperlactacidaemia | 60.82 | 15.01 | 35 | 25658 | 3039 | 32484794 |
Fatigue | 60.62 | 15.01 | 116 | 25577 | 350585 | 32137248 |
Hepatocellular injury | 58.05 | 15.01 | 85 | 25608 | 25233 | 32462600 |
Fall | 57.14 | 15.01 | 43 | 25650 | 196158 | 32291675 |
Congenital anomaly | 57.03 | 15.01 | 26 | 25667 | 1384 | 32486449 |
Febrile neutropenia | 55.83 | 15.01 | 13 | 25680 | 119553 | 32368280 |
Cushing's syndrome | 52.84 | 15.01 | 18 | 25675 | 436 | 32487397 |
Product dose omission issue | 52.38 | 15.01 | 9 | 25684 | 102566 | 32385267 |
CD4 lymphocytes decreased | 51.69 | 15.01 | 28 | 25665 | 2162 | 32485671 |
Acquired immunodeficiency syndrome | 50.93 | 15.01 | 18 | 25675 | 488 | 32487345 |
Dyslipidaemia | 49.32 | 15.01 | 42 | 25651 | 6841 | 32480992 |
Hyperlipidaemia | 49.16 | 15.01 | 59 | 25634 | 14452 | 32473381 |
Osteoporotic fracture | 48.34 | 15.01 | 22 | 25671 | 1166 | 32486667 |
Dyspnoea | 47.92 | 15.01 | 138 | 25555 | 361907 | 32125926 |
Glycosuria | 47.63 | 15.01 | 23 | 25670 | 1395 | 32486438 |
HIV-associated neurocognitive disorder | 47.35 | 15.01 | 16 | 25677 | 378 | 32487455 |
Hypotension | 47.21 | 15.01 | 61 | 25632 | 216049 | 32271784 |
Pneumonia | 44.42 | 15.01 | 139 | 25554 | 355113 | 32132720 |
Mitochondrial cytopathy | 43.27 | 15.01 | 13 | 25680 | 207 | 32487626 |
Osteonecrosis | 42.81 | 15.01 | 59 | 25634 | 16563 | 32471270 |
Lipoatrophy | 42.73 | 15.01 | 17 | 25676 | 644 | 32487189 |
Portal hypertension | 42.51 | 15.01 | 31 | 25662 | 4033 | 32483800 |
Peripheral swelling | 42.39 | 15.01 | 3 | 25690 | 68342 | 32419491 |
Proteinuria | 42.31 | 15.01 | 60 | 25633 | 17295 | 32470538 |
Immunosuppressant drug level increased | 42.29 | 15.01 | 34 | 25659 | 5111 | 32482722 |
Malignant neoplasm progression | 42.08 | 15.01 | 6 | 25687 | 78490 | 32409343 |
Hypophosphataemia | 42.02 | 15.01 | 43 | 25650 | 8832 | 32479001 |
Hepatic failure | 41.57 | 15.01 | 89 | 25604 | 35591 | 32452242 |
Polydactyly | 41.23 | 15.01 | 20 | 25673 | 1225 | 32486608 |
HIV associated nephropathy | 40.20 | 15.01 | 14 | 25679 | 363 | 32487470 |
Cardiac failure congestive | 40.04 | 15.01 | 9 | 25684 | 84843 | 32402990 |
Osteomalacia | 39.89 | 15.01 | 18 | 25675 | 935 | 32486898 |
Liver injury | 39.36 | 15.01 | 52 | 25641 | 14022 | 32473811 |
Coronavirus infection | 38.12 | 15.01 | 28 | 25665 | 3684 | 32484149 |
Constipation | 37.65 | 15.01 | 27 | 25666 | 126346 | 32361487 |
Hepatosplenomegaly | 36.86 | 15.01 | 28 | 25665 | 3875 | 32483958 |
Cerebral toxoplasmosis | 36.83 | 15.01 | 20 | 25673 | 1552 | 32486281 |
Blood triglycerides increased | 36.32 | 15.01 | 51 | 25642 | 14568 | 32473265 |
CD4 lymphocytes increased | 36.14 | 15.01 | 12 | 25681 | 268 | 32487565 |
Ventricular septal defect | 35.59 | 15.01 | 27 | 25666 | 3730 | 32484103 |
Pain | 35.02 | 15.01 | 59 | 25634 | 187497 | 32300336 |
Blood lactic acid increased | 34.49 | 15.01 | 33 | 25660 | 6248 | 32481585 |
Blood pressure increased | 34.40 | 15.01 | 10 | 25683 | 79344 | 32408489 |
Hepatic cytolysis | 33.47 | 15.01 | 37 | 25656 | 8296 | 32479537 |
Hepatitis | 33.43 | 15.01 | 64 | 25629 | 23629 | 32464204 |
Completed suicide | 32.86 | 15.01 | 16 | 25677 | 92501 | 32395332 |
Muscle spasms | 32.17 | 15.01 | 8 | 25685 | 70410 | 32417423 |
Portal fibrosis | 31.78 | 15.01 | 12 | 25681 | 394 | 32487439 |
Gastroschisis | 31.57 | 15.01 | 9 | 25684 | 118 | 32487715 |
Hyperferritinaemia | 31.47 | 15.01 | 12 | 25681 | 405 | 32487428 |
Disease progression | 30.88 | 15.01 | 15 | 25678 | 86847 | 32400986 |
Adrenogenital syndrome | 30.79 | 15.01 | 8 | 25685 | 72 | 32487761 |
Low set ears | 30.69 | 15.01 | 12 | 25681 | 434 | 32487399 |
Lipohypertrophy | 30.49 | 15.01 | 11 | 25682 | 317 | 32487516 |
Cryptorchism | 30.42 | 15.01 | 19 | 25674 | 1915 | 32485918 |
Blood bilirubin increased | 29.40 | 15.01 | 82 | 25611 | 38702 | 32449131 |
Product use in unapproved indication | 28.96 | 15.01 | 141 | 25552 | 87063 | 32400770 |
Atypical mycobacterial infection | 28.73 | 15.01 | 14 | 25679 | 866 | 32486967 |
Maternal drugs affecting foetus | 28.42 | 15.01 | 25 | 25668 | 4252 | 32483581 |
Cholestasis | 27.62 | 15.01 | 64 | 25629 | 26969 | 32460864 |
Acute kidney injury | 27.50 | 15.01 | 353 | 25340 | 293115 | 32194718 |
Bronchopulmonary aspergillosis | 27.18 | 15.01 | 43 | 25650 | 13644 | 32474189 |
Liver disorder | 27.09 | 15.01 | 70 | 25623 | 31584 | 32456249 |
Multiple-drug resistance | 26.97 | 15.01 | 23 | 25670 | 3752 | 32484081 |
Anal cancer | 26.94 | 15.01 | 11 | 25682 | 446 | 32487387 |
Urinary tract infection | 26.73 | 15.01 | 15 | 25678 | 80056 | 32407777 |
Neonatal asphyxia | 26.70 | 15.01 | 10 | 25683 | 321 | 32487512 |
Live birth | 26.38 | 15.01 | 9 | 25684 | 219 | 32487614 |
Epistaxis | 26.19 | 15.01 | 6 | 25687 | 55849 | 32431984 |
Oesophageal candidiasis | 25.79 | 15.01 | 24 | 25669 | 4390 | 32483443 |
Inappropriate schedule of product administration | 25.76 | 15.01 | 3 | 25690 | 45822 | 32442011 |
Taeniasis | 25.76 | 15.01 | 7 | 25686 | 76 | 32487757 |
Drug ineffective for unapproved indication | 25.31 | 15.01 | 42 | 25651 | 13870 | 32473963 |
Renal failure | 25.08 | 15.01 | 187 | 25506 | 134291 | 32353542 |
Urticaria | 24.95 | 15.01 | 8 | 25685 | 59606 | 32428227 |
Acute respiratory distress syndrome | 24.94 | 15.01 | 59 | 25634 | 25194 | 32462639 |
Exomphalos | 24.78 | 15.01 | 8 | 25685 | 163 | 32487670 |
Syphilis | 24.01 | 15.01 | 11 | 25682 | 592 | 32487241 |
Congenital hearing disorder | 23.68 | 15.01 | 7 | 25686 | 105 | 32487728 |
Kidney malformation | 23.67 | 15.01 | 8 | 25685 | 189 | 32487644 |
HIV wasting syndrome | 23.62 | 15.01 | 7 | 25686 | 106 | 32487727 |
Stillbirth | 23.44 | 15.01 | 8 | 25685 | 195 | 32487638 |
Antiviral drug level above therapeutic | 23.09 | 15.01 | 6 | 25687 | 54 | 32487779 |
Jaundice | 22.79 | 15.01 | 69 | 25624 | 34089 | 32453744 |
Back pain | 22.54 | 15.01 | 33 | 25660 | 111020 | 32376813 |
Oesophageal atresia | 22.50 | 15.01 | 10 | 25683 | 501 | 32487332 |
Dizziness | 22.10 | 15.01 | 88 | 25605 | 209530 | 32278303 |
Cortisol decreased | 22.01 | 15.01 | 12 | 25681 | 938 | 32486895 |
Speech sound disorder | 21.90 | 15.01 | 7 | 25686 | 138 | 32487695 |
Pneumocystis jirovecii pneumonia | 21.89 | 15.01 | 47 | 25646 | 18823 | 32469010 |
Adrenal suppression | 21.81 | 15.01 | 11 | 25682 | 733 | 32487100 |
Drug abuse | 21.55 | 15.01 | 19 | 25674 | 80224 | 32407609 |
Splenomegaly | 21.53 | 15.01 | 40 | 25653 | 14437 | 32473396 |
Mycobacterium avium complex infection | 21.30 | 15.01 | 18 | 25675 | 2899 | 32484934 |
Eosinophilia | 21.15 | 15.01 | 55 | 25638 | 24903 | 32462930 |
Endotracheal intubation | 21.07 | 15.01 | 17 | 25676 | 2568 | 32485265 |
Transaminases increased | 21.06 | 15.01 | 55 | 25638 | 24973 | 32462860 |
Somnolence | 20.91 | 15.01 | 31 | 25662 | 103766 | 32384067 |
Small for dates baby | 20.89 | 15.01 | 19 | 25674 | 3374 | 32484459 |
Feeling abnormal | 20.63 | 15.01 | 11 | 25682 | 60412 | 32427421 |
Hepatic function abnormal | 20.62 | 15.01 | 80 | 25613 | 44760 | 32443073 |
Cushingoid | 20.56 | 15.01 | 17 | 25676 | 2657 | 32485176 |
Infection | 20.50 | 15.01 | 22 | 25671 | 84693 | 32403140 |
Gamma-glutamyltransferase increased | 20.36 | 15.01 | 62 | 25631 | 30720 | 32457113 |
Lymphadenopathy | 20.26 | 15.01 | 57 | 25636 | 27025 | 32460808 |
Haemoglobin decreased | 20.21 | 15.01 | 40 | 25653 | 119631 | 32368202 |
Renal tubular acidosis | 20.13 | 15.01 | 15 | 25678 | 2017 | 32485816 |
COVID-19 treatment | 20.11 | 15.01 | 8 | 25685 | 303 | 32487530 |
Burkitt's lymphoma | 20.08 | 15.01 | 7 | 25686 | 182 | 32487651 |
Normal newborn | 20.01 | 15.01 | 7 | 25686 | 184 | 32487649 |
Joint swelling | 19.85 | 15.01 | 8 | 25685 | 51727 | 32436106 |
Lactic acidosis | 19.85 | 15.01 | 65 | 25628 | 33471 | 32454362 |
Castleman's disease | 19.77 | 15.01 | 5 | 25688 | 40 | 32487793 |
Rhabdomyolysis | 19.69 | 15.01 | 105 | 25588 | 67160 | 32420673 |
Hepatic cirrhosis | 19.65 | 15.01 | 42 | 25651 | 16767 | 32471066 |
Erythema | 19.65 | 15.01 | 22 | 25671 | 83083 | 32404750 |
Porphyria non-acute | 19.33 | 15.01 | 9 | 25684 | 503 | 32487330 |
ADAMTS13 activity decreased | 19.23 | 15.01 | 6 | 25687 | 109 | 32487724 |
Faeces pale | 19.10 | 15.01 | 13 | 25680 | 1516 | 32486317 |
Andersen-Tawil syndrome | 19.04 | 15.01 | 4 | 25689 | 12 | 32487821 |
Mixed liver injury | 19.01 | 15.01 | 16 | 25677 | 2564 | 32485269 |
Hyperreflexia | 18.85 | 15.01 | 17 | 25676 | 2987 | 32484846 |
Therapeutic response unexpected | 18.81 | 15.01 | 30 | 25663 | 9582 | 32478251 |
Blood alkaline phosphatase increased | 18.77 | 15.01 | 62 | 25631 | 32070 | 32455763 |
Death neonatal | 18.70 | 15.01 | 8 | 25685 | 365 | 32487468 |
Musculoskeletal toxicity | 18.60 | 15.01 | 6 | 25687 | 122 | 32487711 |
Viral load decreased | 18.59 | 15.01 | 5 | 25688 | 52 | 32487781 |
Neutrophil count decreased | 18.57 | 15.01 | 7 | 25686 | 47132 | 32440701 |
Candida infection | 18.52 | 15.01 | 41 | 25652 | 16762 | 32471071 |
Renal impairment | 18.34 | 15.01 | 130 | 25563 | 91842 | 32395991 |
Low birth weight baby | 18.27 | 15.01 | 25 | 25668 | 6969 | 32480864 |
Hepatomegaly | 18.26 | 15.01 | 31 | 25662 | 10426 | 32477407 |
Protrusion tongue | 18.25 | 15.01 | 7 | 25686 | 240 | 32487593 |
Foetal growth restriction | 18.20 | 15.01 | 19 | 25674 | 3993 | 32483840 |
Pain in extremity | 18.19 | 15.01 | 42 | 25651 | 118859 | 32368974 |
Encephalitis | 18.13 | 15.01 | 25 | 25668 | 7019 | 32480814 |
Blood phosphorus decreased | 18.08 | 15.01 | 17 | 25676 | 3149 | 32484684 |
Cytomegalovirus chorioretinitis | 18.01 | 15.01 | 18 | 25675 | 3594 | 32484239 |
Cachexia | 17.95 | 15.01 | 25 | 25668 | 7084 | 32480749 |
Psoriasis | 17.92 | 15.01 | 7 | 25686 | 46116 | 32441717 |
Hepatotoxicity | 17.83 | 15.01 | 44 | 25649 | 19293 | 32468540 |
Drug hypersensitivity | 17.83 | 15.01 | 19 | 25674 | 73381 | 32414452 |
Pneumococcal infection | 17.63 | 15.01 | 8 | 25685 | 421 | 32487412 |
Sickle cell disease | 17.47 | 15.01 | 6 | 25687 | 149 | 32487684 |
Cellulitis | 17.36 | 15.01 | 9 | 25684 | 50221 | 32437612 |
Loss of consciousness | 17.35 | 15.01 | 24 | 25669 | 82683 | 32405150 |
Chest pain | 17.31 | 15.01 | 46 | 25647 | 124091 | 32363742 |
Caesarean section | 17.29 | 15.01 | 14 | 25679 | 2125 | 32485708 |
Wheezing | 17.21 | 15.01 | 4 | 25689 | 36870 | 32450963 |
Anxiety | 17.16 | 15.01 | 31 | 25662 | 95974 | 32391859 |
Arthralgia | 17.14 | 15.01 | 60 | 25633 | 148388 | 32339445 |
Nephropathy | 16.98 | 15.01 | 22 | 25671 | 5818 | 32482015 |
Prenatal screening test abnormal | 16.96 | 15.01 | 4 | 25689 | 23 | 32487810 |
Hepatitis toxic | 16.79 | 15.01 | 14 | 25679 | 2214 | 32485619 |
Delayed graft function | 16.77 | 15.01 | 13 | 25680 | 1854 | 32485979 |
Cerebral ventricle dilatation | 16.71 | 15.01 | 10 | 25683 | 933 | 32486900 |
Red blood cell schistocytes present | 16.63 | 15.01 | 7 | 25686 | 307 | 32487526 |
Hospitalisation | 16.59 | 15.01 | 9 | 25684 | 48962 | 32438871 |
Hepatitis cholestatic | 16.55 | 15.01 | 26 | 25667 | 8199 | 32479634 |
Congenital abdominal hernia | 16.54 | 15.01 | 4 | 25689 | 26 | 32487807 |
Therapeutic product effect incomplete | 16.52 | 15.01 | 6 | 25687 | 41335 | 32446498 |
Blood pressure decreased | 16.43 | 15.01 | 10 | 25683 | 51070 | 32436763 |
Confusional state | 16.42 | 15.01 | 58 | 25635 | 143057 | 32344776 |
Ergot poisoning | 16.39 | 15.01 | 5 | 25688 | 84 | 32487749 |
Acute hepatitis C | 16.37 | 15.01 | 6 | 25687 | 181 | 32487652 |
Immunoblastic lymphoma | 16.36 | 15.01 | 3 | 25690 | 3 | 32487830 |
Progressive multifocal leukoencephalopathy | 16.31 | 15.01 | 28 | 25665 | 9503 | 32478330 |
Influenza | 16.27 | 15.01 | 8 | 25685 | 46006 | 32441827 |
Cerebrovascular accident | 16.22 | 15.01 | 27 | 25666 | 86293 | 32401540 |
Transient tachypnoea of the newborn | 16.22 | 15.01 | 6 | 25687 | 186 | 32487647 |
Syncope | 16.20 | 15.01 | 29 | 25664 | 90095 | 32397738 |
Pancreatitis acute | 16.19 | 15.01 | 53 | 25640 | 27282 | 32460551 |
Anticoagulation drug level increased | 16.03 | 15.01 | 8 | 25685 | 521 | 32487312 |
Dysmorphism | 15.96 | 15.01 | 15 | 25678 | 2778 | 32485055 |
Chest discomfort | 15.92 | 15.01 | 10 | 25683 | 50220 | 32437613 |
Opportunistic infection | 15.90 | 15.01 | 12 | 25681 | 1645 | 32486188 |
Renal tubular necrosis | 15.42 | 15.01 | 37 | 25656 | 15941 | 32471892 |
Visceral leishmaniasis | 15.40 | 15.01 | 8 | 25685 | 567 | 32487266 |
Mitochondrial myopathy | 15.19 | 15.01 | 6 | 25687 | 223 | 32487610 |
Oral candidiasis | 15.16 | 15.01 | 31 | 25662 | 11996 | 32475837 |
Aspartate aminotransferase increased | 15.09 | 15.01 | 97 | 25596 | 66332 | 32421501 |
Bilirubin conjugated increased | 15.01 | 15.01 | 16 | 25677 | 3442 | 32484391 |
Source | Code | Description |
---|---|---|
ATC | J05AR10 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA MoA | N0000000246 | HIV Protease Inhibitors |
FDA EPC | N0000175889 | Protease Inhibitor |
FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
FDA MoA | N0000190107 | Organic Anion Transporting Polypeptide 1B1 Inhibitors |
FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
CHEBI has role | CHEBI:35660 | HIV protease inhibitors |
CHEBI has role | CHEBI:36044 | anti-virus drug |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D065692 | Cytochrome P-450 CYP3A Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D017320 | HIV Protease Inhibitors |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D011480 | Protease Inhibitors |
MeSH PA | D000084762 | Viral Protease Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Coronavirus infection | off-label use | 186747009 | |
Prevention of HIV Infection after Exposure | off-label use | ||
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
Complete atrioventricular block | contraindication | 27885002 | |
Hereditary factor VIII deficiency disease | contraindication | 28293008 | DOID:12134 |
Torsades de pointes | contraindication | 31722008 | |
Hereditary factor IX deficiency disease | contraindication | 41788008 | DOID:12259 |
Hypokalemia | contraindication | 43339004 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Cardiomyopathy | contraindication | 85898001 | DOID:0050700 |
Prolonged QT interval | contraindication | 111975006 | |
Chronic hepatitis C | contraindication | 128302006 | |
Structural disorder of heart | contraindication | 128599005 | |
Liver function tests abnormal | contraindication | 166603001 | |
Hypomagnesemia | contraindication | 190855004 | |
Second degree atrioventricular block | contraindication | 195042002 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Mixed hyperlipidemia | contraindication | 267434003 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Congenital long QT syndrome | contraindication | 442917000 | |
First Degree Atrioventricular Heart Block | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.03 | acidic |
pKa2 | 12.72 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Multidrug resistance protein 1 | Transporter | IC50 | 4.99 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.07 | CHEMBL | |||||
Pol polyprotein | Enzyme | INHIBITOR | Ki | 10.40 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | WOMBAT-PK | |||||||
CAAX prenyl protease 1 homolog | Enzyme | IC50 | 4.74 | CHEMBL | |||||
Protease | Enzyme | IC50 | 7.60 | CHEMBL | |||||
Protease | Unclassified | Ki | 10.59 | CHEMBL | |||||
Protease | Unclassified | Ki | 10.54 | CHEMBL |
ID | Source |
---|---|
4021228 | VUID |
N0000179581 | NUI |
D01425 | KEGG_DRUG |
4021228 | VANDF |
C0674432 | UMLSCUI |
CHEBI:31781 | CHEBI |
AB1 | PDB_CHEM_ID |
CHEMBL729 | ChEMBL_ID |
D061466 | MESH_DESCRIPTOR_UI |
DB01601 | DRUGBANK_ID |
11504 | IUPHAR_LIGAND_ID |
7798 | INN_ID |
2494G1JF75 | UNII |
92727 | PUBCHEM_CID |
195088 | RXNORM |
15774 | MMSL |
d04716 | MMSL |
008874 | NDDF |
129475001 | SNOMEDCT_US |
387067003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-0522 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 32 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-1575 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 32 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-2605 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 32 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-3956 | SOLUTION | 80 mg | ORAL | NDA | 32 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-6799 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 32 sections |
Lopinavir-Ritonavir | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0527-1947 | SOLUTION | 80 mg | ORAL | ANDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 11819-342 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-362 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Lopinavir and ritonavir | HUMAN PRESCRIPTION DRUG LABEL | 2 | 31722-556 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 27 sections |
Lopinavir and ritonavir | HUMAN PRESCRIPTION DRUG LABEL | 2 | 31722-603 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53808-0276 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5566 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 55289-947 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Lopinavir and Ritonavir | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65015-299 | GRANULE | 40 mg | ORAL | Export only | 1 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 66336-624 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68071-2348 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 25 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 68258-1972 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 27 sections |
Kaletra | HUMAN PRESCRIPTION DRUG LABEL | 2 | 70518-0091 | TABLET, FILM COATED | 200 mg | ORAL | NDA | 26 sections |